•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation
Strong Car Rental Demand Aids Avis Budget Group Amid Low Liquidity
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Avis Wins $650 Million From Hedge Fund That Bet Big on Its Stock
Reasons Why You Should Retain Avis Budget Stock in Your Portfolio
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection
These 10 Stocks Are Getting Crushed By Short Sellers Right Now
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
Why Is Avis Budget (CAR) Down 3.2% Since Last Earnings Report?
A Look at Avis Budget Group Inc (CAR) After 5.9% Gain -- GF Value $130.88 vs Price $174.88
CAR's Strategic Mobility Partnerships Offer Long-Term Opportunities
Avis Budget Group Announces Pricing of $300 Million of Senior Notes